SkinCeuticals is betting on the GLP-1 market.

On Monday, the medical-grade skin care revealed the launch of its A.G.E. Interrupter Ultra Serum, $185, which was developed for and tested on GLP-1 weight loss drug users. While the brand declined to share sales figures, the team said this launch is expected to be its biggest of the year, driving new customer acquisition.

The serum, which joins a lineup of A.G.E. Interruper products including a cream and eye cream, is formulated with 30 percent proxylane and 4.6 percent wild fruit flavonoids to target glycation, which typically leads to aging skin, and support collagen production. 

With these benefits in mind, the product was specifically formulated for GLP-1 users, as rapid weight loss often leads to skin laxity. According to experts, weight loss from a GLP-1 could also lead to a lack of hydration and collagen and lead to looser skin that amplifies fine lines and wrinkles. The SkinCeuticals team, which focuses heavily on the crossover between medical aesthetics and complementary topical products, saw the growing opportunity to tap into the GLP-1 market through skin care solutions. Specifically, 30 million in the U.S. by 2030 could be on a weight loss drug, according to JP Morgan Research. 

“We are laser-focused on medical trends driving consumers to clinics, and that’s how we got the idea to test this A.G.E. Interrupter Ultra Serum with GLP-1 patients,” said SkinCeuticals’ general manager Tara Pyle. “Today is about leveraging the best of science and technology, which is also about the world of aesthetic procedures, including GLP-1s alongside skin care to maximize results. We as a brand are still very driven by scientific breakthroughs. This is the heart of all of our product development.”

As the team has been eyeing the market, Pyle also emphasized that the channels to get prescribed a GLP-1 are growing, particularly as medical spas bet on the drug.

“In some outlets, it’s the number one aesthetic service, which is fascinating. It’s in our channel,” she said. “Weight loss is also a gateway to medical aesthetics involvement. We saw a recent McKinsey paper that [said] 63 percent of GLP-1 patients who start aesthetics do it for the first time after their weight loss….[According to the] American Society of Plastic Surgeons, 41 percent of patients who are prescribed GLP-1s are considering nonsurgical procedures.” 

Additional research from Circana showed that GLP-1 users overindex in a variety of categories, including beauty.

“We tested the regimen with A.G.E. Interrupter Advanced Cream and the new Ultra Serum [on 25 male and female particpants], and we noticed that after [using] the regimen, before even procedures, it visibly reduced skin laxity in just four weeks,” Pyle said. “We also tested with a minimally invasive ultrasound procedure on GLP-1 patients. This also showed an additional reduction in skin laxity by 20 percent.”

As SkinCeuticals looks to future launches, Pyle said the impacts of GLP-1s on the skin will continue to be an area of interest for the brand.

“GLP-1s [are] not going anywhere. It is a major segment of our medical customers, so it will always be a consideration,” she said.